Data Insights

Relacorilant by Corcept Therapeutics for Cushing's Syndrome: Likelihood of Approval

Relacorilant is under clinical development by Corcept Therapeutics and currently in Phase III for Cushing's Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Relacorilant in Cushing's Syndrome

Data Insights

Relacorilant by Corcept Therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval

Relacorilant is under clinical development by Corcept Therapeutics and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - Relacorilant in Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Data Insights

Relacorilant by Corcept Therapeutics for Prostate Cancer: Likelihood of Approval

Relacorilant is under clinical development by Corcept Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Relacorilant in Prostate Cancer

Data Insights

Mifepristone by Corcept Therapeutics for Alcohol Dependence: Likelihood of Approval

Mifepristone is under clinical development by Corcept Therapeutics and currently in Phase II for Alcohol Dependence. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mifepristone in Alcohol Dependence

Data Insights

Miricorilant by Corcept Therapeutics for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval

Miricorilant is under clinical development by Corcept Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...

Data Insights

Zavacorilant by Corcept Therapeutics for Alzheimer's Disease: Likelihood of Approval

Zavacorilant is under clinical development by Corcept Therapeutics and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zavacorilant in Alzheimer's Disease

Data Insights

Zavacorilant by Corcept Therapeutics for Huntington Disease: Likelihood of Approval

Zavacorilant is under clinical development by Corcept Therapeutics and currently in Phase I for Huntington Disease. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zavacorilant in Huntington Disease

Data Insights

Zavacorilant by Corcept Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Zavacorilant is under clinical development by Corcept Therapeutics and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Zavacorilant in Amyotrophic Lateral Sclerosis

Data Insights

Mifepristone by Corcept Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Mifepristone is under clinical development by Corcept Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...